SCHEMBL5008601

SCHEMBL5008601

Cc1cc(F)ccc1-c1cc(Nc2ccccc2C(=O)O)n(-c2ccccc2C)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 12/20 0.47
GFER P55789 1/20 0.45
ADORA2B P29275 1/20 0.45
MAPT P10636 1/20 0.43
MEN1 O00255 1/20 0.41
AKR1B10 O60218 1/20 0.41
TRPA1 O75762 1/20 0.41
ABCB11 O95342 1/20 0.41
DHFR P00374 1/20 0.41
LMNA P02545 1/20 0.41
MPO P05164 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CHRM1 P11229 1/20 0.41
CYP2C9 P11712 1/20 0.41
AKR1B1 P15121 1/20 0.41
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5012049 0.90 ADORA1 (0.49) ADORA1GFERADORA2BMAPTMEN1
SCHEMBL5008470 0.88 ADORA1 (0.62) ADORA1GFERADORA2BMEN1LMNA
SCHEMBL5008323 0.88 ADORA1 (0.54) ADORA1GFERADORA2BMAPTFABP4
SCHEMBL5011993 0.84 ADORA1 (0.52) ADORA1GFERADORA2BMAPTMEN1
SCHEMBL5008839 0.84 ADORA1 (0.47) ADORA1ADORA2BMAPTMEN1LMNA
SCHEMBL5008441 0.84 MAPT (0.47) ADORA1GFERMAPTMEN1LMNA
SCHEMBL5007784 0.83 ADORA1 (0.51) ADORA1ADORA2BMAPTALDH1A1
SCHEMBL5007754 0.81 ADORA1 (0.52) ADORA1GFERADORA2BMAPTMEN1
SCHEMBL5008457 0.81 ADORA1 (0.47) ADORA1ADORA2BMAPTMEN1LMNA
SCHEMBL5011998 0.81 MAPT (0.59) ADORA1GFERADORA2BMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2008-03-13 US disclosed
US-7265144-B2 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes IAPP, GLP1R, GPR119 ADORA1 749/4885GFER 1604/4885ADORA2B 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.